Dr. Arjona Ferreira currently serves as Head of Research and Development and Chief Medical Officer at Organon & Co. (NYSE: OGN) He joins Entera with two decades of clinical development, regulatory execution, and women’s health leadership with roles at Myovant , Shionogi and Merck prior to Organon TEL AVIV, Israel , Oct. 27, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced the appointment of clinical leader Juan Camilo Arjona Ferreira , M.D., to its Board of Directors, effective December 1, 2026 . Dr. Arjona Ferreira will succeed Ms. Haya Taitel , who is stepping down from the Board. “I am delighted to welcome Juan Camilo to Entera’s board. Juan Camilo is a distinguished clinical leader with a valuable track record in late-stage development and regulatory approvals. This, coupled with his particular focus on advancing treatments in women-centric conditions, resonates profoundly with our thesis for EB613 in late-stage development for osteoporosis and EB612 set to enter early clinical development in hypoparathyroidism. On behalf of the Board and our entire team, I would also like to extend my sincere gratitude to Haya Taitel for her commitment and contributions to Entera,” said Miranda Toledano , Chief Executive Officer of Entera. “EB613 represents a paradigm-shifting oral bone-forming treatment that has the potential to significantly expand appropriate care and access for millions of patients with osteoporosis – the majority of which are women after menopause who are at risk,” said Dr. Arjona Ferreira . “In addition, Entera has established a unique oral peptide platform which in and of itself is likely to be valuable across multiple major disease areas. I am excited to join Miranda and her team at this pivotal stage and look forward to supporting Entera’s clinical strategy and regulatory execution.” Dr. Arjona Ferreira is a seasoned physician and pharmaceutical executive and a longtime global advocate for women’s health, with more than 20 years of global clinical development experience. He currently serves as Head of Research & Development and Chief Medical Officer at Organon & Co. (NYSE: OGN), leading Organon’s global research and development organization, which spans early- and late-stage development, global regulatory affairs, pharmacovigilance and safety science, and medical affairs across a diverse portfolio focused on women’s health. Prior to Organon, he served as Chief Medical Officer of Myovant Sciences Inc. , leading global clinical development and medical affairs for innovative therapies in women’s health and oncology, including relugolix combination therapy. Previously, he was Senior Vice President of Clinical Development at Shionogi Inc. , leading clinical strategy and late-stage program execution. Earlier, Dr. Arjona Ferreira spent over a decade at Merck & Co., Inc. (NYSE: MRK) with his last role as Executive Director of Clinical Research in Women’s Health, chairing the product development teams for all programs in contraception and women’s health. Before joining the industry, he practiced as an obstetrician and gynecologist in university hospitals and private practice. Dr. Arjona Ferreira earned his Medical Degree (M.D.) and completed specialist OB-GYN training at the Colegio Mayor del Rosario in Bogotá, Colombia . About Entera Entera is a clinical stage company focused on developing oral peptide and protein replacement therapies for significant unmet medical needs where an oral tablet form holds the potential to transform the standard of care. The Company leverages a disruptive and proprietary technology platform (N-Tab®) and its pipeline of first-in-class oral peptide programs. The Company’s most advanced product candidate, EB613 (oral PTH(1-34)), is being developed as the first oral, osteoanabolic (bone building) once-daily tablet for osteoporosis. A placebo-controlled, dose-ranging Phase 2 study of EB613 tablets (n = 161) met primary (PD/bone turnover biomarker) and secondary endpoints (BMD). Entera is also developing the first oral Long Acting PTH(1-34) tablet as a replacement therapy for patients with hypoparathyroidism (EB612), the first oral oxyntomodulin, a dual targeted GLP1/glucagon peptide tablet for the treatment of obesity and metabolic syndromes; and the first oral GLP-2 tablet as an injection-free alternative for patients suffering from rare malabsorption conditions such as short bowel syndrome in collaboration with OPKO Health, Inc. For more information on Entera, visit www.enterabio.com or follow us on LinkedIn , X (Twitter) , and Facebook . Cautionary Statement Regarding Forward Looking Statements Various statements in this press release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements (other than statements of historical facts) in this press release regarding our prospects, plans, financial position, busin